Format

Send to

Choose Destination
See comment in PubMed Commons below
Biochim Biophys Acta. 2013 Nov;1829(11):1225-35. doi: 10.1016/j.bbagrm.2013.09.007. Epub 2013 Oct 5.

The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs.

Author information

1
Department of Pharmacology & Experimental Therapeutics and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, 1901 Perdido St., New Orleans, LA 70112, USA.

Abstract

Pancreatic angiotensin-converting enzyme 2 (ACE2) has previously been shown to be critical for maintaining glycemia and β-cell function. Efforts to maintain or increase ACE2 expression in pancreatic β-cells might therefore have therapeutic potential for treating diabetes. In our study, we investigated the transcriptional role of hepatocyte nuclear factor 1α (HNF1α) and hepatocyte nuclear factor 1β (HNF1β) in induction of ACE2 expression in insulin-secreting cells. A deficient allele of HNF1α or HNF1β causes maturity-onset diabetes of the young (MODY) types 3 and 5, respectively, in humans. We found that ACE2 is primarily transcribed from the proximal part of the ACE2 promoter in the pancreas. In the proximal part of the human ACE2 promoter, we further identified three functional HNF1 binding sites, as they have binding affinity for HNF1α and HNF1β and are required for induction of promoter activity by HNF1β in insulinoma cells. These three sites are well-conserved among mammalian species. Both HNF1α and HNF1β induce expression of ACE2 mRNA and lead to elevated levels of ACE2 protein and ACE2 enzymatic activity in insulinoma cells. Furthermore, HNF1α dose-dependently increases ACE2 expression in primary pancreatic islet cells. We conclude that HNF1α can induce the expression of ACE2 in pancreatic islet cells via evolutionarily conserved HNF1 binding sites in the ACE2 promoter. Potential therapeutics aimed at counteracting functional HNF1α depletion in diabetes and MODY3 will thus have ACE2 induction in pancreatic islets as a likely beneficial effect.

KEYWORDS:

7-(Methoxycoumarin-4-yl)acetyl-Ala-Pro-Lys(2,4-Dinitrophenyl)-OH; ACE2; Ang; C(t); DPT; HNF1α; HNF1β; MODY; MOI; Mca-APK(Dnp); PPT; Pancreatic islets; Promoter; RAS; RLU; Renin angiotensin system; Transcriptional regulation; angiotensin; angiotensin-converting enzyme 2; cycle-threshold; distal promoter transcripts; eGFP; enhanced green fluorescent protein; hepatocyte nuclear factor 1α; hepatocyte nuclear factor 1β; maturity-onset diabetes of the young; multiplicity of infection; proximal promoter transcripts; relative light units; renin-angiotensin system

PMID:
24100303
PMCID:
PMC3838857
DOI:
10.1016/j.bbagrm.2013.09.007
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Elsevier Science Icon for PubMed Central
    Loading ...
    Support Center